DK0835314T3 - Immunogen detoksificeret mutant af koleratoksiner - Google Patents

Immunogen detoksificeret mutant af koleratoksiner

Info

Publication number
DK0835314T3
DK0835314T3 DK96921043T DK96921043T DK0835314T3 DK 0835314 T3 DK0835314 T3 DK 0835314T3 DK 96921043 T DK96921043 T DK 96921043T DK 96921043 T DK96921043 T DK 96921043T DK 0835314 T3 DK0835314 T3 DK 0835314T3
Authority
DK
Denmark
Prior art keywords
amino acid
immunogenic detoxified
subunit
fragment
escherichia coli
Prior art date
Application number
DK96921043T
Other languages
Danish (da)
English (en)
Inventor
Mariagrazia Pizza
Maria Rita Fontana
Valentina Giannelli
Rino Rappuoli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK0835314T3 publication Critical patent/DK0835314T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96921043T 1995-06-30 1996-07-01 Immunogen detoksificeret mutant af koleratoksiner DK0835314T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513371.6A GB9513371D0 (en) 1995-06-30 1995-06-30 Immunogenic detoxified mutant toxins
PCT/IB1996/000703 WO1997002348A1 (fr) 1995-06-30 1996-07-01 Toxines de cholera mutantes detoxifiees immunogenes

Publications (1)

Publication Number Publication Date
DK0835314T3 true DK0835314T3 (da) 2007-03-26

Family

ID=10776939

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96921043T DK0835314T3 (da) 1995-06-30 1996-07-01 Immunogen detoksificeret mutant af koleratoksiner

Country Status (10)

Country Link
US (2) US7632513B2 (fr)
EP (2) EP0835314B1 (fr)
AT (1) ATE346930T1 (fr)
AU (1) AU6238896A (fr)
DE (1) DE69636735T2 (fr)
DK (1) DK0835314T3 (fr)
ES (1) ES2278385T3 (fr)
GB (1) GB9513371D0 (fr)
PT (1) PT835314E (fr)
WO (1) WO1997002348A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9603314D0 (en) * 1996-02-16 1996-04-17 Biocine Spa Immunogenic detoxified mutant toxins
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP1486215A3 (fr) * 1997-03-21 2006-04-12 Chiron Corporation Mutants détoxifies de toxines bactériennes ribolysant l'ADP utilisés comme adjuvants parentéraux
WO1998045324A1 (fr) * 1997-04-04 1998-10-15 The Uab Research Foundation Utilisation des mutants de la toxine du cholera comme adjuvants muqueux
AU3311599A (en) * 1998-02-25 1999-09-15 Iomai Corporation Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin
DK1117435T3 (da) * 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans
BR9916515A (pt) * 1998-12-22 2001-11-06 Thompson Boyce Plant Res Polinucleotìdeo, vetor de expressão, células de e. coli e de agrobacterium tumefaciens transformadas com o vetor de expressão, célula de planta transgênica, semente de planta transgênica, célula eucariótica transgênica, composição imunogênica, método de evocar uma resposta imune em um animal ou ser humano, planta transgênica, e, adjuvante
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
ES2533085T3 (es) 2001-05-22 2015-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
IL159209A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
CN1977971A (zh) 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
US20060251675A1 (en) * 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP2357000A1 (fr) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Immunisations mucosiques et systémiques avec des particules de réplicon à alpha-virus
WO2009014650A2 (fr) * 2007-07-20 2009-01-29 The General Hospital Corporation Exotoxines recombinantes de vibrio cholerae
US8732716B2 (en) 2008-09-30 2014-05-20 International Business Machines Corporation Virtualization across physical partitions of a multi-core processor (MCP)
US10076563B2 (en) * 2015-04-16 2018-09-18 Inventprise, Llc Bordetella pertussis immunogenic vaccine compositions

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
US4328209A (en) * 1979-04-11 1982-05-04 Board Of Regents, The University Of Texas System Cholera vaccine
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
US4666837A (en) * 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
CA1340373C (fr) * 1986-01-28 1999-02-02 Rino Rappuoli Clonage et sequencage du fragment d'adn qui code les cinq sous-unites de l'anatoxine coquelucheuse, plasmide hybride contenant le fragment d'adnet microorganismes transformes par le plasmide hybride et capables d'exprimer toutes les sous-unites de l'anatoxine coquelucheuse ou certaines d'entre elles
ES2061482T3 (es) 1986-05-02 1994-12-16 Gist Brocades Nv Metodo para la identificacion de secuencias de señal secretora para sintesis de proteina extracelular en bacillus.
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DK0396964T3 (da) 1989-04-28 1995-10-30 Sclavo Spa Pertussistoxin-mutanter, Bordetella-stammer, der er i stand til at producere sådanne mutanter, samt deres anvendelse til udvikling af antipertussis-vacciner
US6413523B1 (en) * 1989-06-02 2002-07-02 The United States Of America As Represented By The Secretary Of The Navy Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
IT1248735B (it) 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US20020044939A1 (en) * 1991-12-31 2002-04-18 Chiron S.P.A. Immunogenic detoxified mutants of cholera toxin
JP3428646B2 (ja) * 1992-06-18 2003-07-22 プレジデント アンド フェローズ オブ ハーバードカレッジ ジフテリア毒素ワクチン
ATE275970T1 (de) 1993-10-05 2004-10-15 Celltech Pharmaceuticals Ltd Impfstoffzusammensetzungen
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6436407B1 (en) * 1994-08-26 2002-08-20 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic adjuvant
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6033673A (en) * 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
HUP0104842A3 (en) 1998-05-08 2002-12-28 Univ Bristol Bristol Vaccine
DK1117435T3 (da) 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans
BR9916515A (pt) * 1998-12-22 2001-11-06 Thompson Boyce Plant Res Polinucleotìdeo, vetor de expressão, células de e. coli e de agrobacterium tumefaciens transformadas com o vetor de expressão, célula de planta transgênica, semente de planta transgênica, célula eucariótica transgênica, composição imunogênica, método de evocar uma resposta imune em um animal ou ser humano, planta transgênica, e, adjuvante
EP1034792A1 (fr) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Administration par voie intranasale de vaccins à base de polyosides de Pneumococcus
AU775695B2 (en) * 1999-03-12 2004-08-12 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US7115730B1 (en) * 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7063852B2 (en) * 2000-05-19 2006-06-20 The Administrators Of The Tulane Educational Fund Hybrid LT-A/CT-B holotoxin for use as an adjuvant
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
CN1977971A (zh) * 2001-06-07 2007-06-13 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
IL159209A0 (en) * 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
US20080112965A1 (en) * 2001-10-01 2008-05-15 Aventis Pasteur Limited Chlamydia OMP antigen
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DE602004020189D1 (de) * 2003-01-30 2009-05-07 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
US20060251675A1 (en) * 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins

Also Published As

Publication number Publication date
EP0835314A1 (fr) 1998-04-15
DE69636735D1 (de) 2007-01-11
US20040137017A1 (en) 2004-07-15
GB9513371D0 (en) 1995-09-06
ATE346930T1 (de) 2006-12-15
EP0835314B1 (fr) 2006-11-29
WO1997002348A1 (fr) 1997-01-23
ES2278385T3 (es) 2007-08-01
US20050136076A1 (en) 2005-06-23
PT835314E (pt) 2007-03-30
US7872114B2 (en) 2011-01-18
US7632513B2 (en) 2009-12-15
AU6238896A (en) 1997-02-05
EP1788087A1 (fr) 2007-05-23
DE69636735T2 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
DK0835314T3 (da) Immunogen detoksificeret mutant af koleratoksiner
TW239146B (fr)
DK0941333T3 (da) Immunogent detoksificeret mutant E. Coli LT-A-toksin
DK364285A (da) Immunogene konjugater af e. coli lt-b enterotoxinunderenhed og kapsulaere polymere
CA2437899A1 (fr) Vaccin pour immunisation transcutanee contre la diarrhee du voyageur causee par l'etec
CN1290174A (zh) 全身性送递口服疫苗及治疗剂的组合物和方法
ATE187078T1 (de) Nichttoxisches schleimhautadjuvans
IL87608A0 (en) Recombinant dna-derived bordetella toxin subunit analogs
CA2154063A1 (fr) Traitement de troubles gastroduodenaux associes a h. pylori
WO2000037609A3 (fr) Enterotoxines bacteriennes immunogenes a administration par voie orale, exprimees dans des plantes transgeniques
Magagnoli et al. Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin
ATE182270T1 (de) Mukosale verabreichung von pneumokokken-antigenen
PT824548E (pt) Moleculas hibridas entre a enterotoxina labil ao calor e a subunidade b da toxina da colera
Pizza et al. Toxins as vaccines and adjuvants
Nagy Vaccines against toxigenic Escherichia coli disease in animals.
IT1190884B (it) Composizione di un immunogeno per la protezione contro la diarrea provocata da escherichia coli enterotossinogena